Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata
NCT05368103
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
30
Enrollment
INDUSTRY
Sponsor class
Conditions
Alopecia Areata
Interventions
BIOLOGICAL:
Daxdilimab
Sponsor
Amgen